BACKGROUND: Human parechovirus (HPeV) causes central nervous system (CNS) infection in infants. To further understand HPeV CNS infection, we describe its clinical, laboratory and epidemiologic characteristics from a Midwestern US tertiary care center. Because HPeV CNS infections have appeared clinically and seasonally similar to enterovirus (EV) infections, we retrospectively compared characteristics of young infants undergoing sepsis evaluations in whom HPeV, EV or neither were detected in cerebrospinal fluid (CSF). METHODS: HPeV real-time reverse-transcription polymerase chain reaction (RT-PCR) assay was performed on frozen nucleic acid extracts of CSF specimens submitted for EV RT-PCR assay from children seen at our hospital in 2009. HPeV genotyping was performed by sequencing of the viral protein 1 region. Clinical data were abstracted from medical records retrospectively for EV-positive, HPeV-positive and age-matched controls in whom neither virus was detected from CSF testing. RESULTS: HPeV was detected in 66 of the 388 (17%) CSF specimens whereas EV was detected in 54 of the 388 (14%) from June through October 2009. Genotyping identified HPeV3 in 51 of the 66 (77%) positive CSF specimens. Males predominated (61%) with the most common presenting symptoms (91%) being fever and irritability. All HPeV-positive patients were <5 months of age. Eight required admission to the pediatric intensive care unit. In multivariate analysis, lower peripheral white blood cell counts with lower absolute lymphocyte count values, higher maximum temperatures, longer fever duration, absence of pleocytosis and longer hospitalization were independently associated with HPeV patients compared with patients with EV or patients negative for both HPeV and EV. CONCLUSIONS: Our data indicate that HPeV3, an emerging CNS pathogen of infants in the United States, should be considered in sepsis-like presentation even without CSF pleocytosis. Addition of HPeV RT-PCR to EV RT-PCR assay for CSF specimens of patients <6 months of age could reduce hospital stay and costs while improving clinical management.
BACKGROUND:Human parechovirus (HPeV) causes central nervous system (CNS) infection in infants. To further understand HPeV CNS infection, we describe its clinical, laboratory and epidemiologic characteristics from a Midwestern US tertiary care center. Because HPeV CNS infections have appeared clinically and seasonally similar to enterovirus (EV) infections, we retrospectively compared characteristics of young infants undergoing sepsis evaluations in whom HPeV, EV or neither were detected in cerebrospinal fluid (CSF). METHODS:HPeV real-time reverse-transcription polymerase chain reaction (RT-PCR) assay was performed on frozen nucleic acid extracts of CSF specimens submitted for EV RT-PCR assay from children seen at our hospital in 2009. HPeV genotyping was performed by sequencing of the viral protein 1 region. Clinical data were abstracted from medical records retrospectively for EV-positive, HPeV-positive and age-matched controls in whom neither virus was detected from CSF testing. RESULTS:HPeV was detected in 66 of the 388 (17%) CSF specimens whereas EV was detected in 54 of the 388 (14%) from June through October 2009. Genotyping identified HPeV3 in 51 of the 66 (77%) positive CSF specimens. Males predominated (61%) with the most common presenting symptoms (91%) being fever and irritability. All HPeV-positive patients were <5 months of age. Eight required admission to the pediatric intensive care unit. In multivariate analysis, lower peripheral white blood cell counts with lower absolute lymphocyte count values, higher maximum temperatures, longer fever duration, absence of pleocytosis and longer hospitalization were independently associated with HPeVpatients compared with patients with EV or patients negative for both HPeV and EV. CONCLUSIONS: Our data indicate that HPeV3, an emerging CNS pathogen of infants in the United States, should be considered in sepsis-like presentation even without CSF pleocytosis. Addition of HPeV RT-PCR to EV RT-PCR assay for CSF specimens of patients <6 months of age could reduce hospital stay and costs while improving clinical management.
Authors: T Hyypiä; C Horsnell; M Maaronen; M Khan; N Kalkkinen; P Auvinen; L Kinnunen; G Stanway Journal: Proc Natl Acad Sci U S A Date: 1992-09-15 Impact factor: 11.205
Authors: H Harvala; I Robertson; T Chieochansin; E C McWilliam Leitch; K Templeton; P Simmonds Journal: J Infect Dis Date: 2009-06-15 Impact factor: 5.226
Authors: W Allan Nix; Kaija Maher; E Susanne Johansson; Bo Niklasson; A Michael Lindberg; Mark A Pallansch; M Steven Oberste Journal: J Clin Microbiol Date: 2008-06-04 Impact factor: 5.948
Authors: H Harvala; I Robertson; E C McWilliam Leitch; K Benschop; K C Wolthers; K Templeton; P Simmonds Journal: J Clin Microbiol Date: 2008-08-27 Impact factor: 5.948
Authors: Jan Felix Drexler; Klaus Grywna; Andreas Stöcker; Patrícia Silva Almeida; Tereza Cristina Medrado-Ribeiro; Monika Eschbach-Bludau; Nadine Petersen; Hugo da Costa-Ribeiro; Christian Drosten Journal: Emerg Infect Dis Date: 2009-02 Impact factor: 6.883
Authors: H Rudolph; R Prieto Dernbach; M Walka; P Rey-Hinterkopf; V Melichar; E Muschiol; S Schweitzer-Krantz; J W Richter; C Weiss; S Böttcher; S Diedrich; H Schroten; T Tenenbaum Journal: Eur J Clin Microbiol Infect Dis Date: 2017-04-13 Impact factor: 3.267
Authors: Justin Sharp; Jeremiah Bell; Christopher J Harrison; W Allan Nix; M Steven Oberste; Rangaraj Selvarangan Journal: J Clin Microbiol Date: 2012-09-26 Impact factor: 5.948
Authors: Elizabeth H Doby; Chris Stockmann; E Kent Korgenski; Anne J Blaschke; Carrie L Byington Journal: Pediatr Infect Dis J Date: 2013-09 Impact factor: 2.129
Authors: Claire M Midgley; Mary Anne Jackson; Rangaraj Selvarangan; Patrick Franklin; Elizabeth L Holzschuh; Jennifer Lloyd; Joseph Scaletta; Anne Straily; Sheri Tubach; Ashley Willingham; W Allan Nix; M Steven Oberste; Christopher J Harrison; Charles Hunt; George Turabelidze; Susan I Gerber; John T Watson Journal: J Pediatric Infect Dis Soc Date: 2018-05-15 Impact factor: 3.164